Nanocarry
Manufacturing · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3 Pinchas Sapir, Illinois, United StatesWebsite
www.nanocarry.comRevenue
<$5 MillionIndustry
About Nanocarry
Nanocarry is focused on developing first-in-class therapeutics aimed at treating brain cancers and central nervous system (CNS) diseases. The company utilizes a proprietary technology platform that enables biologics to overcome the Blood-Brain Barrier, thereby enhancing the delivery of therapeutics to the brain. Their current pipeline includes neuro-oncology treatments for brain metastases and seeks partnerships for developing next-generation therapeutics for neurodegenerative and genetic CNS diseases. Nanocarry's innovative approach aims to revolutionize the treatment landscape for patients suffering from neurological conditions.Explore more
Nanocarry Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Nanocarry
Compare insights from companies similar to Nanocarry, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nanocarry Tech Stack
A closer look at the technologies used by Nanocarry
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nanocarry
Sign Up For FreeTo access detailed company insights
Nanocarry is focused on developing first-in-class therapeutics aimed at treating brain cancers and central nervous system (CNS) diseases. The company utilizes a proprietary technology platform that enables biologics to overcome the Blood-Brain Barrier, thereby enhancing the delivery of therapeutics to the brain. Their current pipeline includes neur... Read More
